Opioid receptors are widely distributed throughout the brain and play an essential role in
modulating aspects of human mood, reward, and well-being. Accumulating evidence …

Since the serendipitous discovery of the first class of modern antidepressants in the 1950's,
all pharmacotherapies approved by the Food and Drug Administration for major depressive …

Abstract Nociceptin/Orphanin FQ (N/OFQ) is an endogenous ligand of the N/OFQ peptide
(NOP) receptor, which is a G protein-coupled receptor in brain regions associated with mood …

This paper is the thirty-ninth consecutive installment of the annual review of research
concerning the endogenous opioid system. It summarizes papers published during 2016 …

Major depressive disorder (MDD) remains one of the leading causes of disability and
functional impairment worldwide. Current antidepressant therapeutics require weeks to …

The discovery of endogenous peptide ligands for morphine binding sites occurred in parallel
with the identification of three subclasses of opioid receptor (OR), traditionally designated as …

Major depressive disorder (MDD) afflicts approximately 5% of the world population, and
about 30–50% of patients who receive classical antidepressant medications do not achieve …

With the emergence of positron emission tomography (PET) in the late 1970s, psychiatry
had access to a tool capable of non‐invasive assessment of human brain function. Early …

Positron emission tomography (PET) is useful for noninvasive in vivo visualization of
disease-related receptors, for evaluation of receptor occupancy to determine an appropriate …

Background This was a proof‐of‐concept study to evaluate the efficacy of LY 2940094, a
nociceptin/orphanin FQ peptide receptor antagonist, in reducing alcohol consumption in …